Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 3 3Phase 1/2 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 2

Conditions

Hematologic Neoplasms 3Myeloproliferative Disorders 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Interventional × fedratinib × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT01420770 2025-03-05

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Bristol-Myers Squibb

Phase 2 Completed
30 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01420783 2025-03-05

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Bristol-Myers Squibb

Phase 2 Completed
81 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01523171 2025-03-05

JAKARTA2

Bristol-Myers Squibb

Phase 2 Completed
97 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡